Nanomedicine for respiratory diseases

Tanaffos

Volumn 11, Issue 4, 2012, Pages 18-22

  Bahadori, Moslem ^a,b   Mohammadi, Forozan ^b  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; CHITOSAN; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GOLD NANOPARTICLE; INTERFERON; ISONIAZID; LIPOSOME; MUCIN 2; MUCIN 5AC; NANOPARTICLE; PADGEM PROTEIN; PROTEIN P53; PYRAZINAMIDE; RIFAMPICIN; SELECTIN; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; TUBERCULOSTATIC AGENT;

AEROSOL; ALLERGIC ASTHMA; ARTICLE; CANCER DIAGNOSIS; CANCER RESISTANCE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE REGULATOR GENE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG SAFETY; GENE EXPRESSION; GENE MUTATION; HUMAN; LIFE EXPECTANCY; LUNG CANCER; LUNG TUBERCULOSIS; NANOMEDICINE; NANOTECHNOLOGY; NONHUMAN; PARTICLE SIZE; PATHOGENESIS; PHYSICAL CHEMISTRY; RESPIRATORY TRACT DISEASE; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 84875168689     PISSN: 17350344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Freitas RA Jr. What is nanomedicine? Dis Mon 2005; 51 (6): 325-41.
2. Miller J. Beyond biotechnology: FDA regulation of nanomedicine. Columbia Sci Technol Law Rev 2003; 4: E5.
3. National Nanotechnology Initiative (NNI) available www.becon.nih.gov/2002html.
4. Rosi NL, Mirkin CA. Nanostructures in biodiagnostics. Chem Rev 2005; 105 (4): 1547-62.
5. National Institute of Health. NIH Roadmap Available at www.nihroadmap.nih.gov/nanomedcine/index.asp (27 Sep 2004).
6. Gessler T. Inhalative pharmacotherapy in the future-- nanocarriers for pulmonary drug delivery. Pneumologie 2009; 63 Suppl 2: S113-6.
7. Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. FASEB J 2005; 19 (3): 311-30.
8. Pison U, Welte T, Giersig M, Groneberg DA. Nanomedicine for respiratory diseases. Eur J Pharmacol 2006; 533 (1-3): 341-50.
9. Sadikot RT. Peptide nanomedicines for treatment of acute lung injury. Methods Enzymol 2012; 508: 315-24.
10. Park HH, Jamison AC, Lee TR. Rise of the nanomachine: the evolution of a revolution in medicine. Nanomedicine (Lond) 2007; 2 (4): 425-39.
11. Rees M, Moghimi SM. Nanotechnology: from fundamental concepts to clinical applications for healthy aging. Nanomedicine 2012; 8 Suppl 1: S 1-4.
12. Bahadori M, Mohammadi F. Nanomedicine. Iranian Journa of Pathology (IJP) 2006; 1(2): 41-8.
13. Mansour HM, Rhee YS, Wu X. Nanomedicine in pulmonary delivery. Int J Nanomedicine 2009; 4: 299-319.
14. Dames P, Gleich B, Flemmer A, Hajek K, Seidl N, Wiekhorst F, et al. Targeted delivery of magnetic aerosol droplets to the lung. Nat Nanotechnol 2007; 2 (8): 495-9.
15. John AE, Lukacs NW, Berlin AA, Palecanda A, Bargatze RF, Stoolman LM, et al. Discovery of a potent nanoparticle Pselectin antagonist with anti-inflammatory effects in allergic airway disease. FASEB J 2003; 17 (15): 2296-8.
16. Kumar M, Kong X, Behera AK, Hellermann GR, Lockey RF, Mohapatra SS. Chitosan IFN-gamma-pDNA Nanoparticle (CIN) Therapy for Allergic Asthma. Genet Vaccines Ther 2003; 1 (1): 3.
17. Kong X, Hellermann GR, Zhang W, Jena P, Kumar M, Behera A, et al. Chitosan Interferon-gamma Nanogene Therapy for Lung Disease: Modulation of T-Cell and Dendritic Cell Immune Responses. Allergy Asthma Clin Immunol 2008; 4 (3): 95-105.
18. Prickett M, Jain M. Gene therapy in cystic fibrosis. Transl Res. 2012 Dec 26.
19. Pandey R, Sharma A, Zahoor A, Sharma S, Khuller GK, Prasad B. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother 2003; 52 (6): 981-6.
20. Bhardwaj A, Kumar L, Narang RK, Murthy RS. Development and characterization of ligand-appended liposomes for multiple drug therapy for pulmonary tuberculosis. Artif Cells Nanomed Biotechnol 2013; 41 (1): 52-9.
21. Machado MC, Cheng D, Tarquinio KM, Webster TJ. Nanotechnology: pediatric applications. Pediatr Res 2010; 67 (5): 500-4.
22. Gonçalves AS, Macedo AS, Souto EB. Therapeutic nanosystems for oncology nanomedicine. Clin Transl Oncol 2012; 14 (12): 883-90.
23. Zarogoulidis P, Chatzaki E, Porpodis K, Domvri K, Hohenforst-Schmidt W, Goldberg EP, et al. Inhaled chemotherapy in lung cancer: future concept of nanomedicine. Int J Nanomedicine 2012; 7: 1551-72.
24. Gopalan B, Ito I, Branch CD, Stephens C, Roth JA, Ramesh R. Nanoparticle based systemic gene therapy for lung cancer: molecular mechanisms and strategies to suppress nanoparticle-mediated inflammatory response. Technol Cancer Res Treat 2004; 3 (6): 647-57.
25. Prabha S, Labhasetwar V. Nanoparticle-mediated wild-type p53 gene delivery results in sustained antiproliferative activity in breast cancer cells. Mol Pharm 2004; 1 (3): 211-9.
26. Broza YY, Kremer R, Tisch U, Gevorkyan A, Shiban A, Best LA, et al. A nanomaterial-based breath test for short-term follow-up after lung tumor resection. Nanomedicine 2013; 9 (1): 15-21.
27. Barash O, Peled N, Tisch U, Bunn PA Jr, Hirsch FR, Haick H. Classification of lung cancer histology by gold nanoparticle sensors. Nanomedicine 2012; 8 (5): 580-9.